Dr. Adria Carbo Appointed as New Scientific Director of BioTherapeutics

Blacksburg, VA, August 1st, 2014 - BioTherapeutics (BTI), a pre-clinical stage, small-molecule company advancing therapeutics for inflammatory diseases and diabetes, announced today that Dr. Adria Carbo has joined BTI to further develop the Company’s growing product portfolio of anti-inflammatory and anti-diabetic compounds. Dr. Carbo worked for 4 years at the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) and the Center for Modeling Immunity to Enteric Pathogens (MIEP) at Virginia Tech. He has been instrumental in establishing a $10 million research portfolio related to infectious and autoimmune diseases at NIMML.

“Dr. Carbo’s addition to the BTI team will provide a wealth of experience and knowledge in translational immunology as demonstrated by his impressive track record of 20 publications during his time at NIMML and MIEP. This important new appointment underscores BTI’s strong commitment to leading the discovery of small molecule drugs for chronic inflammatory and autoimmune diseases. Having worked with Dr. Carbo in my role of Director of NIMML for the last 4 years, I have no doubt that Dr. Carbo, as the new Scientific Director and part of the BTI senior management team, will play a key role in accelerating BTI’s drug development programs.” Said Dr. Josep Bassaganya-Riera, Professor of Immunology and Director of NIMML and MIEP, and President of BTI.

“I am very excited to take on this new challenge and looking forward to working with the talented BTI team to advance our innovative product pipeline towards investigationalnew drug (IND) approval by the Food and Drug Administration (FDA),” Dr. Carbo noted. “BTI’s and my personal commitment to team science will help accelerate the next steps of pre-clinical efficacy and safety testing of novel compounds for the treatment of inflammatory bowel disease and type 2 diabetes. We will take advantage of the great momentum that BTI is experiencing with recent funding from VBHRC and NIH to bring our products and services to the market.”

Dr. Carbo earned his B.S. in Biotechnology from the University of Vic, Spain, and his PhD in Genetics, Bioinformatics and Computational Biology under the direction of Dr. Bassaganya-Riera from Virginia Tech in 2014. He received training in mucosal immunology, nutritional immunology, bioinformatics, pre-clinical efficacy and safety testing, and computational modeling of immunological processes in infectious and immune-mediated diseases.

About NIMML

The NIMML Institute is a 501 (c) (3) non-profit public charity foundation focused on a transdisciplinary, team-science approach to precision medicine at the interface of immunology, inflammation, and metabolism. The NIMML Institute team has led numerous large-scale transdisciplinary projects and is dedicated to solving important societal problems by combining the expertise of immunologists, computational biologists, toxicologists, modelers, translational researchers, and molecular biologists. The Institute is headquartered in Blacksburg, VA. For more information, please visit www.nimml.org or contact pio@nimml.org.